Medbot-B Toumai surgical robot orders top 300 units globally

Medbot-B's Toumai laparoscopic surgical robot accumulated more than 300 commercial orders globally, with first-half 2026 bookings exceeding the full-year 2025 total, as the Chinese-made system gains traction against Intuitive Surgical's da Vinci franchise.

"The rapid accumulation of the aforesaid orders will help consolidate the group's future revenue base and have a positive impact on the group's operating performance for the year 2026," the board said in a stock exchange filing on June 16.

As of June 16, cumulative orders across Medbot-B's three core specialties — laparoscopic, orthopedic and vascular intervention — totaled almost 400 units. The Toumai system alone accounted for more than 300 of those orders. The company has completed commercial installations in more than 60 countries and regions, up from about 40 at the end of 2025.

The milestone positions Medbot-B to challenge Intuitive Surgical, which has installed more than 9,500 da Vinci systems worldwide since the late 1990s and generated $6.1 billion in revenue in 2024. Medbot-B shares rose 13.6% on the announcement, giving the company a market value of about HK$22 billion ($2.8 billion). The board expects the order momentum to support 2026 revenue growth.

Intuitive Surgical's da Vinci system remains the dominant platform in robotic surgery, with more than 9,500 installations and an estimated 85% share of the global market. Medbot-B's Toumai, which received China's National Medical Products Administration approval for laparoscopic surgery in 2022, competes primarily on price and local market access. Chinese-made surgical robots typically cost 30% to 50% less than comparable da Vinci models, according to industry estimates, though Medbot-B has not disclosed specific pricing for the Toumai system.

The global surgical robotics market was valued at about $8 billion in 2024 and is projected to grow at a compound annual rate of 17% through 2030, driven by adoption in emerging markets and expansion into new surgical specialties, according to Grand View Research. Medbot-B's Toumai platform covers laparoscopic, orthopedic and vascular procedures, positioning it to capture share across multiple segments.

Medbot-B trades on the Hong Kong Stock Exchange under the ticker 02252.HK. The company has not yet reported profitability, and investors will watch whether the order pipeline translates into recognized revenue and margin improvement. The 60-country installation base provides a diversified revenue stream, though the company faces regulatory and competitive hurdles in markets such as the US and Europe, where Intuitive Surgical and Johnson & Johnson's Ottava robot are established. Analysts will look for updates on gross margin and system utilization rates in the company's next earnings report.

This article is for informational purposes only and does not constitute investment advice.